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Background 
The implementation of value based healthcare (VBHC) in inflammatory arthritis (IA) requires a 
standardized set of modifiable outcomes and risk-adjustment variables that is feasible to implement  
worldwide.  
Methods 
The International Consortium for Health Outcomes Measurement (ICHOM) assembled a 
multidisciplinary working group, consisting of 24 experts from six continents, including six patient 
representatives, to develop a Standard Set of outcomes for IA. The process followed a structured 
approach using a modified Delphi process to reach consensus on 1) conditions covered by the set, 2) 
outcome domains, 3) outcome measures, 4) risk-adjustment variables. Consensus on decision areas two to 
four were supported by systematic literature reviews and consultation of experts.  
Results 
The ICHOM IA Standard Set covers patients with rheumatoid arthritis (RA), axial spondyloarthritis, 
psoriatic arthritis and juvenile idiopathic arthritis (JIA). We recommend that the following outcomes be 
collected at least annually: pain, fatigue, activity limitations, overall physical and mental health impact, 
work/school/housework ability and productivity, disease activity, and serious adverse events. Validated 
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measures for patient-reported outcomes were endorsed, and linked to common reporting metrics. Age, 
sex at birth, educational level, smoking status, comorbidities, time since diagnosis, and rheumatoid factor 
and anti-citrullinated protein antibody lab testing for RA and JIA should be collected as risk-adjustment 
variables. 
Conclusion 
We present the ICHOM IA Standard Set of outcomes that enables healthcare providers to implement the 
value based healthcare framework and enable comparison of outcomes important to patients with IA.   
 
Significance & Innovation 
 Standards for measuring and comparing   treatment outcomes that matter to patients 
with inflammatory arthritis that are globally implementable are currently lacking 
 We used a modified Delphi procedure and systematic reviews of the literature to develop 
a Standard Set of Outcomes that matter to patient with inflammatory arthritis 
 The patient reported outcome measures we recommend for measuring pain, activity 
limitations, fatigue and assessment of overall emotional and physical health impact were 
linked to a common Item response theory based common metric, so that users of the set 
can select their preferred instrument for measuring these outcomes 
 
Introduction 
The inflammatory arthritides are a group of systemic, immune mediated rheumatic conditions, 
characterized by synovitis or inflammation of periarticular tissues and joint damage. The life time 
risk of adult onset inflammatory arthritis (IA) has been estimated to be  about 6% of the 
population in the United States (1). The availability of strategies to diagnose the diseases earlier, 
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and the availability of biological and targeted small molecule therapies, in combination with early, 
tight controlled treatment strategies have led to relevant improvements in outcomes for many 
patients over the last decades (2,3). However, these improvements have also resulted in an 
increased financial burden on healthcare systems  (4,5).  
The prevalence and case recognition of IA is expected to rise further over the next decade, 
particularly in less economically developed countries (6).  Hence it will be increasingly important 
to optimize care and allocate available resources efficiently to improve or maintain quality of 
care. Value Based Healthcare  (VBHC) is a framework for improving the quality and efficiency 
of healthcare, in which improving value for the patient is the central concept (7). Value is defined 
as the patient outcomes achieved, relative to financial costs for obtaining those outcomes. Within 
this framework, value can be increased by improving patient outcomes or by delivering the same 
outcomes at a lower cost. Public reporting of patient outcomes by healthcare providers is 
proposed as a mechanism that will accelerate identification and adoption of high value care, 
through shared learning and promoting benchmarking of outcomes that matter to patients.  
In order for outcomes to be comparable between different healthcare providers, exact 
definitions for each relevant outcome are required. The outcomes need to be feasible  to 
collected in a variety of healthcare systems and a set of relevant risk-adjustment variables should 
be included to ensure risk-adjusted comparisons of outcomes between providers that serve 
different patient populations. The  International Consortium for Health Outcomes Measurement 
(ICHOM) initiative is working toward the global implementation of VBHC by  developing 
Standard Sets of patient outcomes for a range of medical conditions (8).  These standards are 
intended to be implemented in routine clinical practice and therefore complement earlier core 
sets and reporting standards intended for clinical research, including the  work of the Outcome 
Measures in Rheumatology (OMERACT) group (10). 
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The ICHOM process  is   grounded in a conceptual framework which distinguishes three 
hierarchically ordered tiers of outcome:  health status achieved/retained, the process of recovery 
and sustainability of health (9). To select the most relevant outcomes, outcome measures and risk 
adjustment variable for particular conditions,  various stakeholders including  patients, 
physicians, policy makers and outcome experts  are engaged in  a consensus building process that 
is supported by a systematic evaluation of the available evidence base, including critical 
evaluation of available instruments and evidence supporting their measurement properties.    
To further encourage the adoption and implementation of VBHC in rheumatology, we set out to 
develop a globally applicable set of outcome measures that reflect outcomes that matter to 
patients with IA, for providers to track in their clinical practice. 
Methods 
Working group 
A working group of outcome experts (n = 24) was convened by ICHOM. Working group 
members were carefully selected to ensure representation of relevant professional disciplines, 
different geographic areas, and the patient perspective. The working group included patient 
representatives (n = 6), registry leaders, and members with a professional background in: adult 
and pediatric rheumatology; nursing; epidemiology; psychology; rehabilitation medicine; 
physiotherapy; and psychometrics. Working group members of all 6 inhabited continents were 
included. The efforts of the working group were guided and facilitated by a core project team. 
Working group process 
A modified Delphi approach was used that has been developed by ICHOM and was previously 
applied by ICHOM to develop standards for a number of other conditions (10,11,20–26,12–19) 
The process involved reaching consensus in four major decision areas 1) which IA conditions 
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and treatments to include in the Standard Set, 2) a minimally sufficient set of outcomes relevant 
for each of the conditions, 3) standardized definitions and time points for assessing these 
outcomes, and 4) standardized definitions for risk-adjustment variables to ensure fair 
comparisons between healthcare providers who wish to implement the set. Each decision area 
was discussed during a dedicated videoconference. A list of potentially relevant items (i.e. 
conditions/domains/time points/risk-adjustment variables) to be included in the Standard Set, 
along with supporting evidence (see below), was prepared by the project team preceding each 
meeting. These items were identified in a series of systematic literature reviews and/or 
consultation with external experts on the topic under consideration. A summary of the 
preparatory work was provided to working group members preceding each videoconference. 
During each meeting, the items were discussed and expanded on or revised based on the input 
of the working group. Following each videoconference, the project team circulated a summary of 
the discussions and a survey asking working group members to provide feedback and vote on 
each item considered for inclusion in the Standard Set. For voting during the final survey, a 9-
point Likert scale ranging from 1 – “not recommended” to 9 – “essential to have” was used. 
Items were included in the Standard Set if rated ≥ 7 by at least 70% of the working group or 
excluded if rated ≤ 3 by at least 70% of the working group. In other cases, the result was 
considered inconclusive and the item was discussed again during the following videoconference. 
The conduct and reporting of the Delphi process followed reporting guidelines for core outcome 
set development using the Delphi approach (see supplemental file 1 ) (27).  
Pre-selection of relevant patient outcome domains 
Preceding the videoconference on ‘selection of outcome domains’, two separate systematic 
literature reviews were performed in December 2016 in the PubMed database to identify 
outcomes relevant to patients for the included conditions, that were modifiable in principle  and 
feasible to implement. In the first search we used the “Cochrane Highly Sensitive Search Strategy 
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for identifying randomized trials” (28) to identify 25 recent randomized trials in each of the 
conditions included in the Standard Set. For each randomized trial, we checked the relevant 
online repositories and conducted a second PubMed search using the name of each trial and trial 
registration number to find additional publications on the same study. All outcomes assessed in 
each trial were extracted. Reports on randomized trials in languages other than English were 
excluded. In the second search we identified reports on qualitative studies in which patients with 
one of the relevant conditions were asked about the most important outcomes of their disease. 
We included only papers in which an open-ended question format was used, to prevent 
investigator-imposed biases on the list of patient-generated outcome domains. All outcome 
domains considered important by patients were extracted from each paper by two reviewers 
independently. Disagreements were resolved during a consensus meeting with a third referee 
present. Previously published core set recommendations for outcome measurement in 
randomized trials were also consulted, as was the EULAR standardized dataset for observational 
research (29–33). Finally, two patient advisory group sessions with IA patients from the 
Netherlands and the USA were organized by the project team to serve as a check on the 
comprehensiveness of the list of identified patient outcomes. The patient advisory group 
protocol was exempt from ethical review by the Chesapeake Institutional Review Board. 
Pre-selection of Outcome measures 
All outcome measures used in any randomized trial identified in the initial systematic review, 
recommended for inclusion by working group members or previously endorsed by relevant 
consensus statements, were considered for inclusion. The instruments were reviewed with 
respect to: outcome domains, evidence supporting psychometric properties, feasibility, licensing 
fees, and degree to which they were established in the field. To support this process, a systematic 
literature review was performed in May 2017 to identify papers reporting on the measurement 
properties of 26 potentially relevant Patient-reported outcome measures (PROMs). The 
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methodological quality of the 159 identified papers was assessed using the COSMIN checklist 
(34). The studies that were of high methodological quality were then used to rate the 
measurement properties of the 26 PROMs, using quality criteria proposed by Terwee et al. and 
ISOQOL (35,36). Understandability, cost and time to complete were all assessed to determine 
the feasibility of implementing specific PROMs. The Flesch-Kincaid grade level was calculated 
for the English language version of each PROM (37), information about fees payable for use of 
the instrument was retrieved from the copyright owner’s website when applicable, and 
information on time to complete was retrieved from a previous series of reviews (38).  
Pre-selection of risk-adjustment variables 
A preliminary list of risk-adjustment variables was extracted from published reviews on risk 
factors and validated risk models. Previously published ICHOM Standard Sets were reviewed for 
definitions of demographic and socioeconomic variables.  
External validation by health professionals and patient experts 
After proceeding through all the Delphi rounds, the preliminary Standard Set was made available 
and sent to various stakeholders for review via www.ichom.org. A patient survey was distributed 
via national patient organizations and the networks of the project team and working group 
members. Patients were asked to rate the importance of each outcome using a 9-point Likert 
scale ranging from “1 = not at all relevant” to ”9 = essential” and were given the opportunity to 
suggest additional outcomes. Health professionals were recruited via the professional networks 
of the working group members and project team. Health professionals were asked to rate the 
relevance of each domain, provide feedback on feasibility of implementation of the Standard Set 
in clinical practice, and rate the appropriateness of the risk-adjustment variables and time points 
for assessment.  
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Results  
Scope  
At the start, it was recognized by the working group that the same treatment goals and 
longitudinal outcomes (pain, physical function, fatigue) are  relevant to most types of IA. The 
ICHOM IA Standard Set was therefore designed to evaluate treatment outcomes of patients with 
rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), as well as 
juvenile idiopathic arthritis (JIA) and applies to all treatments for these conditions, including 
medication, surgery, and physical and occupational therapies. All working group members voted 
to include RA, axSpA and PsA, and 82% voted to include JIA. The inclusion of gout (59% voted 
to include initially), connective tissue diseases (41%) and vasculitis (36%) was also considered, 
especially as few outcome recommendations are available  for the latter two conditions. 
However, after revisiting this topic at a subsequent meeting it was decided that their inclusion 
might lead to a generic set of outcomes, which might insufficiently capture the outcomes that 
matter to patients with individual conditions due to the variety of disease manifestations and 
disease courses.  
Outcome domains  
Twenty-four outcome domains were initially identified in the 130 randomized trial reports and 
28 qualitative studies that were identified in the systematic literature reviews (references are 
available on request from the corresponding author). This list was expanded upon and refined 
several times based on group discussions with working group members. The final consolidated 
list of outcomes is presented in table 1, together with a summary of both systematic reviews and 
the final voting results. The list of outcome domains assessed in randomized trials and their rank 
ordering reflects a preference in trials for clinical measures of disease manifestations and patient-
reported outcomes of symptoms and their direct impact on functioning. The list and rank 
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ordering of patient-generated outcome domains on the other hand somewhat deemphasized the 
importance of outcome measures that reflect the pathophysiology of the specific disease and 
included a wider variety of outcomes that reflect the different ways arthritis impacts the daily 
lives of patients. Besides PROMs of symptoms and basic functioning, the patient-generated list 
also included more generic outcomes such as overall psychological wellbeing and participation 
restrictions. To characterize the core symptoms and their direct effect on functioning from the 
patient perspective, the working group recommends that providers assess pain, fatigue, and 
activity limitations (i.e. physical function). These were the most frequently used outcome 
domains in randomized trials and were reported as important by patients in almost all of the 
reviewed qualitative studies. They were also the most frequently endorsed domains in the 
individual core sets for randomized trials of the respective conditions. To assess impact of IA on 
the daily lives of patients more broadly, the working group recommends an assessment of overall 
emotional and physical health impact, and work/school/housework productivity. Participation 
restrictions other than work or school productivity were also considered important. However, 
this domain was eventually excluded because of significant overlap with other included domains 
and because experience with available measurement instruments is currently limited.  
Assessments of inflammatory disease activity and therapeutic response are further recommended 
as measures of disease control, because the absence of signs and symptoms of disease is the 
primary treatment target for IA and disease activity was considered the main determinant of 
overall impact of disease. Finally, adverse events should be recorded as a measure of disutility of 
care.  
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Outcome measures  
The list of recommended patient-reported outcome measures (PROMs) is presented in table 2. 
Supplemental file 2 provides an overview of characteristics and ratings assigned to the 
measurement properties of these PROMs and includes an overview of the criteria used for 
assigning ratings. 
The Working Group agreed that a key property was feasibility in different settings globally. 
Therefore, instruments with a large number of items, or that cannot be hand-scored were 
avoided. All endorsed PROMs are available in multiple languages and for each outcome domain, 
at least one PROM is recommended that was judged to have sufficient evidence supporting its 
measurement properties, based on the results of the systematic review. On the other hand, some 
instruments were included that do not (yet) meet psychometric standards of the COSMIN 
checklist. Several PROMIS measures were included so that experience with innovative Item 
Response Theory (IRT) based measures can accumulate.  The rheumatoid- and psoriatic- 
arthritis impact of disease scores (RAID and PSAID) and ASAS Health index were 
recommended because these are patient/ICF -derived composite scores assessing the important 
domains of impact of RA and PSA, and AxSpA respectively. Supplemental file 3 provides an 
overview of the various measures that are recommended by the clinical guidelines issued by 
various national and international rheumatology societies. For each of the ICHOM outcome 
domains, the endorsed outcome measures are congruent with the various guidelines.    Users of 
the Standard Set may select preferred instruments to assess each outcome from the list of 
endorsed PROMs presented in table 2. The shortest recommended combination of PROMs to 
assess all outcome domains is NRS/VAS to measure fatigue, overall emotional and physical 
health impact, and pain; the Work Productivity and Activity Impairment questionnaire (WPAI) 
to measure work/school/housework ability and productivity, and the Health Assessment 
Questionnaire II (HAQ-II) to measure activity limitations. This combination of PROMs is free 
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to use for all users and totals 19 questions, which most patients should be able to fill out in 5 
minutes. The endorsed PROMs of pain, fatigue, overall wellbeing and activity limitations have 
been linked to a common reporting metric, such that outcomes can be compared between 
providers that have used different instruments (39). Linked scores for benchmarking outcomes 
using any of the recommended instruments of the Standard Set can be obtained from 
www.tihealthcare.nl/en/expertise/common-metrics.   
To track disease activity and therapeutic response, it is proposed that major evidence-based 
guidelines are followed (40,41). Patients and healthcare providers should specify target disease 
activity levels for individual patients (preferably remission; if not, feasible low disease activity) 
and assess at each visit whether or not this target was achieved. Disease activity should be 
monitored using a validated and internationally recognized clinical composite score.  
 
Risk-adjustment variables 
Most risk-adjustment variables included in the set (table 3) apply to all patients and care was 
taken to include risk-adjustment variables that are relevant and applicable in a variety of 
healthcare systems. Year of birth and sex were included as demographic variables. Educational 
level was ultimately chosen as the only indirect measure of social economic status (SES). Other 
SES-related variables were considered important, but difficult to collect, due to restrictions on 
recording race/ethnicity in some countries, area-based measure of SES possibly not being 
available for each country, and patients potentially feeling reluctant to report on their 
income/wealth. For baseline status indicators, we included smoking status, comorbidities, 
diagnosis, time since diagnosis, and rheumatoid factor and ACPA for RA and JIA. HLA B27 was 
excluded snice it is not routinely collected in healthcare system. Comorbidities should be 
assessed using the Rheumatic Disease Comorbidities Index (42), modified to include central 
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sensitization to pain (e.g. fibromyalgia) and obesity. To avoid misclassification of early symptoms 
that may or may not reflect those specific to the IA diagnosis of interest we elected to include 
time since diagnosis rather than time since symptom onset.  
Data collection time points 
To allow meaningful outcomes comparisons between healthcare providers, we recommend all 
risk-adjustment variables to be collected at the first assessment. All PROMs and clinical 
measures should also be collected at the first assessment and annually thereafter. In instances of 
active disease, we recommend that the patient’s disease activity status is recorded again at least 
every six months, but likely more frequently, at the discretion of the patient and their healthcare 
provider. Adverse events should be collected at each assessment point after baseline. A reference 
guide with detailed instructions for implementation and exact definitions for all the data elements 
can be downloaded from www.ICHOM.org. Finally, we stress that these recommendations are 
intended only for quality improvement purposes and should not be understood as more than 
minimally acceptable clinical guidelines in patients with established disease. Especially in patients 
with early disease, more frequent monitoring may be required. 
 
Open review 
Eighty-three healthcare professionals, the majority of which (95%) were clinician/researchers, 
and 630 people living with IA from the United States, France, Argentina, the Netherlands and 
Brazil reviewed the Standard Set. All outcomes included in the ICHOM IA set were considered 
very relevant by patients and healthcare professionals (figure 1). Similar to the results of the 
systematic reviews for identifying outcome domains, patients considered clinical measures 
slightly less relevant compared with the patient-reported outcomes. A large majority of patients 
(81.3%) felt that the set comprehensively covers all the relevant outcome domains of their 
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disease. The healthcare professionals predominantly shared this view. Only three outcomes were 
suggested to be missing by more than 1 reviewer: financial impact (n=2), joint damage (n=2) and 
patient satisfaction (n=3). Psychological wellbeing (12.6%) and participation restrictions (5.4%) 
were the only outcomes that were reported as missing from the set by >2% of patient reviewers 
(supplemental file 2). The included risk-adjustment variables were rated very relevant by 91.8% 
of health professionals.  
Discussion 
We present a Standard Set of outcomes for IA that healthcare providers worldwide can use in 
routine clinical care to help quantify the value provided for patients in different centers, 
countries and healthcare systems. This Standard Set was developed through consensus of an 
international working group with expertise across a range of disciplines relevant to outcome 
assessment and care for patients with IA. We used a multiple methods approach, in which 
extensive patient input as well as published qualitative and quantitative data were used to develop 
a minimally sufficient set of outcomes that we believe represents outcomes that matter to 
patients with IA. We also proposed time points for data collection and relevant risk-adjustment 
variables to enable comparisons between providers with different patient populations. Feasibility 
of implementation in different healthcare systems was a central priority. Therefore, we included 
PROMs that are not only widely accepted measures of the respective domains but that are also 
available in multiple translations, and for each outcome there is at least one PROM free to use. 
However, for the use of several instruments: PedsQL, SF-6D, FACIT and EQ-5D license fees 
may apply. PROMIS has also introduced financial charges for the use of some of their products, 
including their computerized adaptive tests. Using the PROMIS Assessment Centre platform will 
incur a $5000 USD charge per study per year.  
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One of the challenges faced with international standardization of patient outcomes data 
collection is that a variety of well validated and frequently used PROMs are typically available to 
assess the different patient outcomes. The working group for the ICHOM Depression & 
Anxiety and Chronic Kidney Disease Standard Sets previously responded to this by endorsing 
PROMs that can be mapped to the PROMIS metric, using resources provided by the PROMIS 
PROsetta project (43,44). This way, users of these sets use one PROM for each domain, but 
results can be scored on the PROMS metric. In the work on the ICHOM IA Standard Set 
presented here, this is taken one step further again by linking multiple PROMs to an IRT based  
common reporting metric (45). This makes it easier for new or ongoing data collection initiatives 
to contribute their data since it allows users of the ICHOM IA set to choose one instrument 
from a number of alternatives for each domain. Provided one of the endorsed instruments 
presented in table 2 is collected, outcomes can be compared with other healthcare providers that 
use the ICHOM Standard Set. For example, outcomes assessed using the VAS fatigue scale can 
be directly compared with outcomes of a different group of patients assessed using FACIT 
fatigue. In principle, PROMs could be added to and removed from the list of endorsed 
instruments, without affecting comparability of the outcomes.  The ICHOM list of 
recommended PROMS overlaps significantly with current clinical guidelines. Moreover, the  
results of  two systematic reviews of various national RA patients registries show that the 
majority of the PROMs that are  currently collected in the reviewed registries are also included in 
the ICHOM IA Standard Set. The IRT approach also allows  each of the ICHOM IA outcomes 
to  be assessed using computerized adaptive tests, which  would help achieve optimally precise 
scores with minimal numbers of questions   (46,47) 
Since the Standard Set is intended to reflect outcomes that are important to patients, the 
extensive input from patients is a strength of this work. We included 6 patient representatives in 
the working group, derived the list of outcomes from published qualitative studies in which 
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patients reported outcomes that matter to them, organized two patient advisory group sessions 
with patients that were not included in the working group to review the final list of outcomes to 
be voted on by working group members, and 630 patients from various countries reviewed the 
final version of the Standard Set. The inclusion of working group members with diverse 
geographic and professional backgrounds is also a strength. We do however acknowledge that 
different results might have been obtained had other working group members been selected. We 
also realize that it may prove challenging to collect all the requested information for all 
healthcare providers at all time points. In particular, inflammatory disease activity may prove 
logistically challenging to track in some healthcare systems, as it requires clinical assessment of 
joint involvement and, in some cases, laboratory assessments. In such situations, we would 
encourage users of the set to at least monitor the PROMs. All patient-reported outcomes can be 
collected using a minimum of 20 items, which could be further reduced using computerized 
adaptive testing or targeted short forms. We finally acknowledge that the value of the ICHOM 
IA Standard Set has not yet been proven in practice. ICHOM aims to partner with a number of 
interested institutions to pilot-test the Standard Set. Furthermore, a steering committee has been 
established that will periodically review the Standard Set, including lessons learnt from the pilot 
phase and other applications of the Standard Set. This will include but will not be limited to 
reviewing: PROMs that are endorsed in the IA Standard Set PROMS; how easy these PROMS 
are to access and monitor;  and outcomes related to personal goals that individual patients 
identify.  
In summary, we propose a Standard Set of outcomes for patients with IA that providers of care 
for patients with IA can track to facilitate the global reporting of outcome data and shared 
learning.  A detailed reference guide is available at www.ichom.org.  
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